Condition: Cancer · Sponsor: MiraKind
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
This description comes directly from the study's public registry record.
Joanne Weidhaas, MDPhD · 203-671-1308 · joanne@mirakind.org
Joanne Weidhaas · 424-387-8100 · Joanne@miradx.com
Always discuss trial participation with your own doctor first.
| MiraKind | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02253251